Science & technology

Science & technology

Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.

Overview

Our pipeline

Matrix-M™ adjuvant

Recombinant protein-based nanoparticle vaccine

Global vaccine authorization / approval map

COVID-19 UPDATES

Novavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.

Learn more about our COVID-19 updates
Who we are

Who we are

We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.

Our company

Executive leadership

Senior management team

Board of directors

Our partners

Build your future with us

Join other passionately curious people who are bringing innovative vaccines to the world

Discover career opportunities
Insights

Insights

Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.

Articles

Diversity matters: Inclusivity in clinical trials

From pandemic to endemic: Why COVID-19 may be here to stay

Standing on the shoulders of giants: How a Novavax vaccine is developed

Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation

Latest clinical presentation

Latest clinical presentation
(2.4 MB)

Latest quarterly earnings

Latest quarterly earnings
(3.4 MB)

Annual report

Global ticker

NASDAQNVAX

Latest press releases Events & presentation Reports & financials SEC filings Stock details & analyst coverage

Recent News

May 26, 2022

FDA Confirms Vaccines and Related Biological Products Advisory Committee Review of Novavax’ COVID-19 Vaccine on June 7, 2022

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the U.S. Food and...

Learn more

May 25, 2022

Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through 15

Novavax is participating in a stage of the COVID-19 Vaccine Schedule Combinations (Com-COV) program initiated by the University of Oxford and supported by the UK Vaccine Taskforce and the National...

Learn more

May 20, 2022

Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over

Novavax today announced the submission of a request to the European Medicines Agency to expand the conditional marketing authorization (CMA) of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine in the...

Learn more

All press releases

Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Governance documents

Novavax board committees

Audit committee charter

Compensation committee charter

Nominating and corporate governance committee charter

Research & development committee charter

Code of Conduct

Hotline policy

Corporate governance guidelines

Get notifications for investor updates